Page 504«..1020..503504505506..510520..»

RNA map of cell nucleus reveals new insights into gene regulation and cell division – University of Toronto

Posted: March 25, 2022 at 2:37 am

Most people are familiar with the cell nucleus from grade school biology as a storage compartment for DNA. But the nucleus also contains several distinct structurescalled nuclear bodies or domains and some of them are brimming with genes messages, also known as RNA transcripts.

Scientists are just now beginning to understand these structures, with University of Toronto researchers recently reportingthe first large-scale survey of RNA transcripts that are associated with different nuclear bodies in human cells.

The work, published in the journalMolecular Cell, suggests that the structures act as hubs to co-ordinate gene regulation and cell division.

It was known that some nuclear domains contain RNA, but the composition of that RNA was not systematically probed in previous studies, saidBenjamin Blencowe, senior author on the study and a professor of molecular genetics in the Donnelly Centre for Cellular and Biomolecular Researchat the Temerty Faculty of Medicine.

Our data has shed light not only on the RNA composition of different nuclear domains, but also provides clues as to the functions of some of these domains.

Until now, the information on nuclear body composition has trickled in piecemeal because there were no methods enabling a systematic survey of RNA localized to these structures. But post-doctoral researcher Rasim Barutcuand graduate studentMingkun Wurealized they could apply a method called APEX-Seq, which had been developed by scientists at Stanford University and the University of California, Berkeley.

APEX is an enzyme that can be fused to any protein of interest and allows labeling of RNAsand other biomoleculesin its proximity. The labeled RNAs can then be isolated and identified by sequencing. By fusing APEX to various marker proteins residing in the different nuclear bodies, Barutcu and Wu were able to create RNA maps for each.

The pair collaborated withUlrich Braunschweig, a senior research associate in Blencowes lab, and with the groups of:Anne-Claude Gingras, a senior scientist at the Lunenfeld-Tanenbaum Research Institute,Sinai Health System, and professor of molecular genetics;Philipp Maass, a scientist at TheHospital for Sick Children andassistant professor of molecular genetics;andRobert Weatheritt,a principal investigator at theGarvan Institute of Medical Research inAustralia.

The team discovered swaths of novel RNAs from several hundred to thousands across the nuclear bodies. Previously, only a handful of transcripts were known to be associated with some of these structures, said Barutcu, whose research was supported by the Banting Postdoctoral Fellowship and a fellowship from the Canadian Institutes of Health Research (CIHR).

One piece of data immediately struck the researchers: The nuclear bodies known as speckles were associated with surprisingly high numbers of RNA transcripts with retained introns segments that do not code for proteins. When a gene is transcribed into RNA, introns must be spliced out in the nucleus before the transcript can be released into the cells interior to serve as a template for making proteins.

The finding led them to realize that speckles are associated with a class of introns with delayed splicing. The nature of the transcripts provided a clue to their function. They were transcribed from genes that control various aspects of gene regulation and the cell division cycle. Genes controlling cell cycle progression must be activated in a timely manner so that their protein products are made only when they are needed. Errors in this process are well known drivers of cancer.

The researchers came up with a model in which the role of the speckles might be to co-ordinate intron removal from transcripts in order to regulate their release from the nucleus, and their subsequent translation into protein factors required for gene regulation and the cell cycle. This mechanism would help ensure a rapid response to cellular signals to make the right kinds of proteins at the right time.

Furthermore, when speckles were disrupted, this altered the splicing of the retained introns, including those located in genes that are directly involved in control of the cell cycle, supporting the idea that the speckles are linked to cell cycle progression.

The model opens up new ways of thinking about cell cycle regulation with implications for cancer research, said Blencowe, who holds a Canada Research Chair in RNA Biology and Genomics and Banbury Chair in Medical Research.

Weve uncovered a mechanism involving differential intron retention linked to speckle integrity that could play an important role in not just normal cell division but also how it goes wrong in cancers, he said, noting that the project was made possible by the now defunct CIHR Foundation grant scheme, which provided long-term research funding.

In addition to the speckles, the team also found large numbers of intron-retained transcripts associated with the nuclear lamina, which forms at the periphery of the nucleus. However,the functional significance of this observation remains unclear.

The researchers said they hope others in the field will take advantage of their datasets and open new avenues of research into nuclear body function where many questions remain.

Read the original here:
RNA map of cell nucleus reveals new insights into gene regulation and cell division - University of Toronto

Posted in Molecular Genetics | Comments Off on RNA map of cell nucleus reveals new insights into gene regulation and cell division – University of Toronto

The Changing Treatment Landscape and the Role of Surgery in RCC – Cancer Network

Posted: March 25, 2022 at 2:37 am

Gennady Bratslavsky, MD, spoke about the evolution for treatments in renal cell carcinoma and how surgery may play a role.

The role of surgery for renal cell carcinoma (RCC) and strategies used for treatment are ever evolving. As options for systemic therapies continually improve, many clinicians are opting to spare patients from undergoing procedures.

Gennady Bratslavsky, MD, professor and chair of the Department of Urology and director of the Prostate Cancer Program at Upstate Medical University in Syracuse, New York, recently hosted a presentation on the role of surgical in management in RCC at the 15th Annual Interdisciplinary Prostate Cancer Congress and Other Genitourinary Malignancies, hosted by Physicians Education Resource, LLC (PER).

I still think that there will be appropriately selected patients [for whom] surgery will remain the first and potentially the main type of treatment. We may even include metastasectomy [for some as] that has been used for years, said Bratslavsky.

In an interview with CancerNetwork, Bratslavsky spoke about what role surgery currently plays in RCC, new strategies on the horizon, and trials he is most excited to see read out.

This is an evolving landscape. We are going to try to operate less on patients who we can avoid surgery, were going to try to prognosticate better and see who can be spared. The term intervention-free survival is something that will hopefully be used more and more. Some trials are being designed, for example, in a role for renal biopsy where type of surgery or timing of surgery may be affected.

The role of surgery for more advanced disease is also ever changing. Obviously, the dogma that every metastatic kidney cancer can be removed is wrong, [but] his can still render patients disease free and offer a durable long-term survival.

The adjuvant [therapy] space is finally having some promise with the recently published KEYNOTE-564 trial [NCT03142334]. Adjuvant pembrolizumab [Keytruda] certainly [provides] an opportunity for us to expect and hope for disease-free survival [DFS]. Most of the adjuvant trials to date have not been more successful [than KEYNOTE-564]. Even in the S-TRAC [NCT00375674] trial of adjuvant [sunitnib; Sutent] utilization for a year after nephrectomy in patients with the kidney cancer that were found to be high risk, the presence of DFS never translated into overall survival [OS].

While KEYNOTE-564 is yet to matureto demonstrate whether its use in the adjuvant setting would help with OS is yet to be determinedthere is certainly quite a bit of hope that after 2 years of follow up, were starting to see a promise and a strong signal that this DFS may translate into OS, although this has yet to be seen. The recently completed PROSPER trial [NCT03055013] is bringing another opportunity for us to evaluate the role of immunotherapy in the neoadjuvant as well as the adjuvant setting for high-risk patients. There are many unanswered questions. Even if we identify an agent that is effective in improving DFS, we will always question the patients who would have not recurred and still would be subjected to therapy. There is still an ongoing need for better identification of these patients that are most likely to recur beyond our standard clinical variables that have been traditionally used in designing the trials for both neoadjuvant and an adjuvant therapy.

Any research [conducted] has an enormous impact [on] the molecular subcategorization of renal neoplasms, the understanding of genetics, branched evolution, our ability to detect the circulating tumor DNA, and the numerous structures that still contain many of the genetic material and prognostic information. All of this has an enormous potential [for clinical impact].

Were continuously learning about new pathways that may bring in more systemic options, with the biggest breakthrough [being] in our continued appreciation of how heterogeneous kidney cancer is as a disease, how heterogeneous the molecular characteristics are, and how heterogeneous the clinical course and the metastatic potential of each tumor is. These are not tumors that are created equal. They possess very different clinical behaviors and opportunities for targeted or immunotherapies. Research is strong.

Our lab at SUNY Upstate Medical University focuses on the role of molecular chaperones in identification of potential targets and how activity of chaperones can be modified. Our lab has been creating new avenues for therapeutics. Numerous centers and laboratories are doing a great job in identifying these new avenues into how this cancer can be targeted or identified, and even the identification of some biomarkers for better disease response. [There are many paths] that were trying to tackle from different angles.

Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385(8):683-694. doi:10.1056/NEJMoa2106391

View post:
The Changing Treatment Landscape and the Role of Surgery in RCC - Cancer Network

Posted in Molecular Genetics | Comments Off on The Changing Treatment Landscape and the Role of Surgery in RCC – Cancer Network

Research Associate, Crop Genomics job with UNIVERSITY OF WESTERN AUSTRALIA | 286656 – Times Higher Education

Posted: March 25, 2022 at 2:37 am

The School of Biological Sciences

Batley Lab Crop Genomics

About the team

The School of Biological Sciences is a large, multidisciplinary School with over 80 high-calibre staff delivering world-class education and research programs to approximately 600 undergraduate and postgraduate coursework students and is responsible for the supervision of ~100 PhD students. The School is research-intensive with expertise in the disciplines of Computational Biology, Ecology & Conservation, Evolutionary Biology, Neuroscience and Science Communication.

The Batley lab studies genetics and genomics on a range of crop and pathogen species, including subterranean clover, soybean, wheat, banana and chickpea, with other projects on a wide range of species including parasitic plants and pearl oyster, however our primary research focus is on the agricultural oilseed crop Brassica napus (canola), and its interactions with the disease-causing fungus Leptosphaeria maculans (blackleg).

Related research projects include identification of blackleg disease resistance genes in canola using next-generation sequencing and high-throughput molecular marker approaches. New projects are investigating the role of structural variation in the Brassica genomes, specifically in relation to disease resistance and understanding the evolution of disease resistance genes. In conjunction with this our lab continues to work on development of genomes and pan genomes.

About the role

You, as the successful appointee, will be responsible for research projects investigating plant pathogen interactions and evolution of disease resistance genes and preparing and publishing scientific publications with a focus on crop plants.

You will also be involved in project planning, execution of molecular experiments, data analysis and interpretation, preparation of scientific manuscripts for publication and participation in the supervision of other research personnel engaged in the projects.

To be considered for this role, you will demonstrate:

Full details of the position's responsibilities and the selection criteria are outlined in the position description.

Closing date:Friday, 20 May 2022

This position is open to international applicants.

Application Details: Please apply online via the Apply Now button.

Our commitment to inclusion and diversity

UWA is committed to a diverse workforce. We celebrate inclusion and diversity and believe gender equity is fundamental to achieving our goal of being a top 50 university by 2050.

See the original post:
Research Associate, Crop Genomics job with UNIVERSITY OF WESTERN AUSTRALIA | 286656 - Times Higher Education

Posted in Molecular Genetics | Comments Off on Research Associate, Crop Genomics job with UNIVERSITY OF WESTERN AUSTRALIA | 286656 – Times Higher Education

Research – Stony Brook University

Posted: March 25, 2022 at 2:37 am

Three Minute Thesis (3MT), a spoken-word thesis competition held annually at Stony Brook, is an opportunity for graduate students to present their dissertation research findings to a general audience in three minutes with only one PowerPoint slide. The goal is for students to engage all their communication skills to make their research vivid and engaging while emphasizing its key point without technical terminology or field-specific jargon.

Graduate students receive specialized coaching and professional development that uses a cohort approach to encourage peer feedback and support. The Alumni Association sponsors prizes for the best talks: First Prize: $1,000, Second Prize: $700, Third Prize: $500 and Peoples Choice: $300. Talks are evaluated by a panel of judges from a range of backgrounds and disciplines for how well the speaker engages a general audience of non-specialists and can convey the excitement and innovation of their research without jargon or distortion.

The final round of this years competition will be held live via Zoom on Wednesday, April 6, at 4 pm and streamed on stonybrook.edu/3mt.

The 2022 3MT competitors are:

Farzana Ali, Biomedical Engineering, Advisor: Christine DeLorenzoCaitlyn Cardetti, Molecular and Cellular Pharmacology, Advisor: Daniel Bogenhagen Allen Chen, Neuroscience, Advisor: Qiaojie XiongXinan Chen, Applied Mathematics and Statistics, Advisor: Allen TannenbaumMarcy Ekanayake-Weber, Interdepartmental Doctoral Program in Anthropological Sciences, Advisor: Andreas KoenigShrin Feiz-Disfani, Computer Science, Advisor: IV RamakrishnanLesia Guinn, Biomedical Engineering, Advisor: Gabor BalazsiMoises Hassan Bendahan, Hispanic Languages and Literature, Advisor: Kathleen VernonJessica Hautsch, English, Advisor: Amy CookKathryn Hill, Neuroscience, Advisor: Ramin ParseyErwei Huang, Chemistry, Advisor: Ping Liu (BNL)Samruddhi Jewlikar, Biochemistry and Structural Biology, Advisor: Peter TongeSin-ying Lin, Clinical Psychology, Advisor: Nicholas Eaton Yu Chung Lin, Materials Science and Chemical Engineering, Advisor: Miriam RafailovichXiaoyang Liu, Materials Science and Chemical Engineering, Advisor: Yu-Chen Karen Chen-WiegartDevon Lukow, Genetics, Advisor: Jason SheltzerAlok Mishra, Computer Science, Advisor: Barbara ChapmanPhilip Opsasnick, Philosophy, Advisor: Anne OByrneGiancarlo Pasquini, Social and Health Psychology, Advisor: Stacey ScottDerek Pope, Science/STEM Education, Advisor: Angela KellyAnthony Ripa, Computer Science, Advisor: Aaditya RanganDeborah Rupert, Neuroscience, Advisor: Stephen SheaHeidi Schneider, Music, Advisor: Jeremy LittleDamion Scott, Philosophy, Advisor: Harvey CormierAlyssa Stansfield, Atmospheric Science, Advisor: Kevin ReedLiu Yang, Electrical Engineering, Advisor: Petar Djuric

The winner of Stony Brooks 3MT 2022 competition will have the opportunity to represent Stony Brook in the Northeastern regional competition.

Read story "Three Minute Thesis Competition Final is April 6" on SBU News

More:
Research - Stony Brook University

Posted in Molecular Genetics | Comments Off on Research – Stony Brook University

The people cloning their pets – BBC.com

Posted: March 25, 2022 at 2:36 am

"People ask me, 'Why is it so expensive?' and I tell them because there are so many complicated steps involved in the whole process," says Rodriguez. "It's definitely an emotional reason for pet clients. They want to be able to carry on that strong emotional bond that they have with the pet."

The industry has since expanded elsewhere in the globe. Sooam Biotech in South Korea offer dog cloning services, as well as Sinogene in China.

However, many scientists remain uncomfortable about the whole premise. Lovell-Badge argues that there is "no justification" for pet cloning as while the resulting animals will be genetically identical, they will not have the same behavioural characteristics and personalities as all creatures are a product of both genes and their environment.

"People really want their pet that knows them and knows certain tricks and so forth," says George Church, professor of genetics at Harvard Medical School. "In that sense, it's a little bit taking advantage of people's grief."

Reviving extinct species

In the years that followed Dolly's cloning, the central question was whether scientists would ever extend the technology to humans, and the many moral and ethical issues that would invoke.

But while a human embryo was successfully cloned in 2013, the process of creating an entire human being has never been attempted because of the likely public outcry. Chinese scientists did clone the first primates in January 2018, long-tailed macques Zhong Zhong and Hua Hua, but there are currently no suggestions that this work will continue into further primate species.

Instead, most funding is being devoted to using cloning to resurrect animals on the verge of extinction. Efforts are underway to clone both the giant panda and the northern white rhino a species for which there are just two animals left on the planet while in the last two years, ViaGen have cloned the black footed ferret and Przewalski's horse, both of which are endangered.

Church is leading the most ambitious project, a quest to revive the woolly mammoth, a species that last lived some 4,000 years ago. His de-extinction company Colossal has already raised 11m ($14.5m) in funding to support the idea, which will involve creating an elephant-mammoth hybrid through taking skin cells from Asian elephants and using cloning technology to reprogram them with mammoth DNA.

Read more from the original source:
The people cloning their pets - BBC.com

Posted in Human Genetics | Comments Off on The people cloning their pets – BBC.com

Antibodies From COVID Infection Shield Kids for Up to 7 Months – HealthDay News

Posted: March 25, 2022 at 2:36 am

TUESDAY, March 22, 2022 (HealthDay News) -- Antibodies from a COVID-19 infection linger in most children for up to seven months, even if they had no symptoms, a new study finds.

To come to that reassuring conclusion, researchers analyzed data from 218 children in Texas, ages 5 to 19, who were enrolled in an ongoing survey launched in October 2020 to track COVID-19 antibody status in children and adults over time.

Blood samples were collected from participants before vaccines became available and during the surges of the Delta and Omicron variants.

While 96% of children who were infected with COVID-19 still had antibodies at least six months later, 58% did not have infection-triggered antibodies at their third and final blood test.

The report, published March 18 in the journal Pediatrics, did not assess the impact of vaccination.

"This is the first study from the Texas CARES survey that includes data from all three time points in the survey," said corresponding author Sarah Messiah. She is a professor of epidemiology, human genetics and environmental sciences at the University of Texas Health Science Center at Houston.

"These findings are important because the information we collected from children infected with COVID-19 didn't differ at all by whether a child was asymptomatic, severity of symptoms, when they had the virus, were at a healthy weight or had obesity, or by gender," she added in a university news release. "It was the same for everyone."

To date, 14 million children in the United States have tested positive for the virus, and these findings help improve understanding of how it affects children, according to Messiah.

"Adult literature shows us that natural infection, plus the vaccine-induced protection, gives you the best defense against COVID-19. There has been a misunderstanding from some parents who think just because their child has had COVID-19, they are now protected and don't need to get the vaccine," Messiah said.

"While our study is encouraging in that some amount [of] natural antibodies last at least six months in children, we still don't know the absolute protection threshold," she added. "We have a great tool available to give children additional protection by getting their vaccine, so if your child is eligible, take advantage of it."

More information

For more on children and COVID-19, go to the American Academy of Pediatrics.

SOURCE: University of Texas Health Science Center at Houston, news release, March 18, 2022

From Your Site Articles

Related Articles Around the Web

See original here:
Antibodies From COVID Infection Shield Kids for Up to 7 Months - HealthDay News

Posted in Human Genetics | Comments Off on Antibodies From COVID Infection Shield Kids for Up to 7 Months – HealthDay News

‘There are two blood proteins that could hold the key to a long, healthy life’ – The Mirror

Posted: March 25, 2022 at 2:36 am

Dr Miriam Stoppard reports on a discovery which could help us to understand the ageing process and how key proteins could help us to live longer, healthier lives

Image: Getty Images)

For years, Ive followed the research on ageing that seeks to slow down the process. So are we any closer to achieving what could be the Holy Grail of medicine?

Studies from Edinburgh University investigating which proteins could influence how we grow old hint that we might be.

In the largest genetic study of ageing, scientists have uncovered two blood proteins that influence how long and healthy a life well live.

Their ambition is to develop drugs that target these proteins as a way of slowing down the whole process.

From adulthood onwards our bodies are in inevitable decline, which results in age-related diseases and eventually death.

The rate at which we age and die depends on genetics, lifestyle, environment and chance. This study reveals the part played by the proteins (the genetics) in this process.

Image:

Our levels of these are determined by the DNA we inherit from our parents and they, in turn, affect our health.

Scientists combined the results of six large genetic studies into ageing totalling hundreds of thousands of people. They studied 857 proteins and identified two that had powerful negative effects on growing older.

For instance, people who inherited DNA that causes raised levels of these proteins were frailer, had poorer self-rated health, and were less likely to live an exceptionally long life than those who didnt.

So, what do these proteins do? The first, LPA, is made in the liver and thought to play a role in blood clotting.

High levels of LPA can increase the risk of hardening of arteries which leads to heart disease and stroke.

The second protein, VCAM1, resides on the lining of blood vessels and controls their expansion and contraction in blood clotting and the immune response.

Levels of VCAM1 increase when we have an infection and this gingers up the immune system.

The researchers say with drugs that lower levels of LPA and VCAM1, we might improve the quality and length of our lives.

Theres already a clinical trial testing a drug to lower LPA as a way of diminishing the risk of heart disease, and VCAM1 in early animal studies improved cognition during old age.

The identification of these two key proteins could help extend the healthy years of life, says Dr Paul Timmers, lead researcher at the MRC Human Genetics Unit at Edinburgh University.

Drugs that lower these protein levels in our blood could allow the average person to live as healthy and as long as individuals whove won the genetic lottery and are born with genetically low LPA and VCAM1 levels.

Brave new world!

See more here:
'There are two blood proteins that could hold the key to a long, healthy life' - The Mirror

Posted in Human Genetics | Comments Off on ‘There are two blood proteins that could hold the key to a long, healthy life’ – The Mirror

Neal Copeland and Nancy Jenkins elected Fellows of the AACR Academy – EurekAlert

Posted: March 25, 2022 at 2:36 am

image:Neal G. Copeland, Ph.D. view more

Credit: MD Anderson Cancer Center

HOUSTON Neal G. Copeland, Ph.D., and Nancy A. Jenkins, Ph.D., both professors of Genetics atThe University of Texas MD Anderson Cancer Center, have been elected to the 2022 class of Fellows of the American Association for Cancer Research (AACR) Academy.

The husband-and-wife geneticists, who co-led a joint laboratory for nearly 40 years, are recognized for their contributions to cancer genetics and for innovations to create mouse models of cancer and a variety of other human diseases.

The mission of the AACR Academy is to honor distinguished scientists whose contributions have propelled significant innovation and progress against cancer. This years class of 33 inductees joins 256 existing fellows in working collectively to advance the mission of the AACR.

Copeland and Jenkins join 10 additional MD Anderson fellows, including current members James P. Allison, Ph.D., Ronald A. DePinho, M.D., V. Craig Jordan, Ph.D., Margaret L. Kripke, Ph.D., Guillermina (Gigi) Lozano, Ph.D., and Louise C. Strong, M.D. Former members, now deceased, include Isaiah J. Fidler, D.V.M., Ph.D., Emil J Freireich, M.D., Waun Ki Hong, M.D., and John Mendelsohn, M.D.

We are so pleased to see Neal and Nancy recognized for their lasting impacts in the field of cancer research and human health, said Peter WT Pisters, M.D., president of MDAnderson. These remarkable scientists pioneered many of the approaches still used in cancer biology today, and we applaud their selection as part of this group of exceptional fellows.

Copeland and Jenkins together developed many of the earliest techniques to model human cancer in mice using insertional mutations. They were among the first to show that the Sleeping Beauty transposon could be mobilized within cells to insert itself within other genes and drive cancer formation. This technique enabled researchers to identify many of the genes and signaling pathways that we now know drive cancer development.

Using the Sleeping Beauty system, they modeled 16 different types of cancer affecting 10 organ systems and validated many of the cancer-related genes discovered through this work. They continue to collaborate in defining genes involved in the progression and metastasis of pancreatic cancer using laser-capture microdissection to isolate specific cancerous lesions followed by whole genome amplification and DNA sequencing.

They also developed a liquid-phase, capture-based sequencing and bioinformatics pipeline to facilitate the sequencing of transposon insertion sites from single tumor cells, making it possible to study tumor evolution at the single-cell level and to unambiguously identify cooperating cancer genes.

Neal and Nancy helped to establish foundational approaches to cancer research that continue to yield new insights, said Giulio F. Draetta, M.D., Ph.D., chief scientific officer. Their work epitomizes our efforts to pursue impactful discovery research to drive cancer breakthroughs, and we are proud to have them as a part of our MD Anderson research community.

Copeland received his bachelors degree in biology and a doctoral degree in biochemistry from the University of Utah.

Jenkins received her bachelors degree in chemistry from Sweet Briar College. She earned a masters degree in microbiology and a doctoral degree in molecular and cellular biology from Indiana University.

The couple met during their postdoctoral fellowship at Dana-Farber Cancer Institute, after which they started a laboratory together at the University of Cincinnati. They spent 21 years together leading research at the National Cancer Institute, followed by five years at the Institute of Molecular and Cell Biology in Singapore. They joined the Houston Methodist Research Institute in 2011 and MD Anderson in 2017.

Copeland and Jenkins each are members of the National Academy of Sciences and The Academy of Medicine, Engineering and Science of Texas. Among numerous honors, they were awarded the 2020 Prince Hitachi Prize for Comparative Oncology. They have co-authored more than 800 peer-reviewed scientific publications.

- 30 -

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Here is the original post:
Neal Copeland and Nancy Jenkins elected Fellows of the AACR Academy - EurekAlert

Posted in Human Genetics | Comments Off on Neal Copeland and Nancy Jenkins elected Fellows of the AACR Academy – EurekAlert

Hypothyroidism can cause hearing loss and tinnitus – Healthy Hearing

Posted: March 25, 2022 at 2:34 am

Not long ago, I lost my hearingagain. As usual, I first blamed my phone for the muffled voices on the other end. Then, the loud, high-pitched ringing in my ears started, making everything even harder to hear. Finally, when I couldn't hear the TV on maximum volume, I was forced to turn on captions.

After a week of hoping it would clear up on its own, my hearing problem became intolerable, and I finally made a doctors appointment. It took ten minutes for the ENT to vacuum out the impacted earwax blocking my eardrum, and my hearing immediately returned to normal. If I sound familiar with this routine, its because Ive been through it several times. I have an underactive thyroid, hypothyroidism, which makes me more likely to develop earwax problems.

The thyroid is a small, butterfly-shaped gland located in the neck that controls energy and metabolism. My hypothyroidism is caused by Hashimoto's disease, a common autoimmune condition. Hashimoto's and hypothyroidism affect an estimated 15 to 20 million Americans. But many of those patientsand even some health care providersarent aware of the connection between thyroid conditions and hearing loss. So, let's take a look at this critical and often overlooked link.

Hearing loss falls into three primary categories:

The symptoms of hearing loss can vary and include:

Hashimotos diseasealso known as Hashimotos thyroiditisis the most common autoimmune disease in the U.S. In any autoimmune disease, the immune system produces antibodies that inappropriately target our organs, glands, tissues or cells. Several autoimmune diseases are linked to hearing loss, including Hashimoto's.

In Hashimotos, antibodies target the thyroid and gradually impair its ability to produce thyroid hormone. Over time, it usually leads to the deficiency in thyroid hormone known as hypothyroidism.

The common signs and symptoms of Hashimotos and hypothyroidism include fatigue, weight gain, hair loss, dry skin, body aches, brain fog, cold hands and feet, depression, anxiety, menstrual irregularities, and constipation, among others.

To diagnose hypothyroidism, doctors use blood tests, including Thyroid Stimulating Hormone (TSH), and available free levels of thyroid hormones Thyroxine (Free T4) and Triiodothyronine (Free T3.) Elevated TSH and low Free T4 and Free T3 levels are evidence of hypothyroidism. A positive result on the Thyroid Peroxidase Antibodies (TPOAb) test can confirm a Hashimotos diagnosis.

The treatment for hypothyroidism is thyroid hormone replacement medication, usually generic levothyroxine, a synthetic form of the T4 hormone. (Synthroid and Levoxyl are well-known brands.) Brand-name Tirosint gel cap and Tirosint-SOL liquid levothyroxine are also available. Some patients benefit from combination replacement therapy, taking generic liothyronine or Cytomel, a synthetic T3 hormone, with their levothyroxine treatment. Finally, some hypothyroid patients feel best taking a different medicationnatural desiccated thyroid (NDT)because it includes natural forms of both T4 and T3 hormones. Apart from generic tablets, currently available brands of NDT include Armour and NP Thyroid.

Hypothyroidism can actually cause sensorineural hearing loss, a connection that was first reported in medical studies all the way back in 1907. Despite this knowledge, more research is needed to determine just how common it is to have both conditions.

Regardless, there's good news for people with hearing loss who are newly diagnosed with hypothyroidism: Treating thyroid disease can help with hearing loss.

According to Sapna Shah, M.D., a board-certified endocrinologist with Paloma Health, "In the instance where thyroid dysfunction is causing hearing loss, studies find that hearing loss improves after a patient starts levothyroxine therapy. In fact, one recent study found that six to twelve months of optimal thyroid hormone replacement treatment improved hearing in nearly 50 percent of the hypothyroid patients studied. Hearing loss was completely reversed in 15 percent of the patients!

Yet, even with proper treatment for thyroid disease, there's still an increased risk of hearing loss. One study estimated that 25 percent of hypothyroid patients have evidence of some degree of mild to moderate sensorineural hearing loss. Symptoms like tinnitus are more common with hypothyroidism, and hearing loss typically develops over time.

Pat G. developed tinnitus 20 years ago when she was diagnosed with hypothyroidism. According to Pat, when she shared her tinnitus symptoms with her doctor, he told her he had tinnitus too and that there was nothing to be done.

Then, just in the last year, says Pat, I noticed that Im having trouble understanding conversations on TV, especially when they play loud background music. I know I need to see a hearing specialist soon. I had no idea any of this could be caused by my hypothyroidism!"

At least one study has indicated that people with hypothyroidismespecially those over 50also face an increased risk of sudden sensorineural hearing loss (SSNHL). With SSNHL, also known as sudden deafness, rapid hearing loss occurs immediately, or within 72 hours. SSNHL requires immediate medical attention because early diagnosis and prompt treatment can help around 85 percent of patients regain some or all of their hearing. Interestingly, optimal thyroid treatment is also a factor in recovery from SSNHL; research shows that patients with higher levels of thyroid hormones have better SSNHL treatment results.

Finally, congenital hypothyroidism (CH) is also linked to hearing loss. Before and after birth, thyroid hormone is essential for the healthy development and functioning of the entire auditory system. Babies born with CH have a life-long risk of hearing loss three times higher than the general population. Mild hearing loss occurs in around 20 percent of CH patients, and once they reach early adulthood, an estimated 17 percent of CH patients require hearing support. Hearing experts recommend that CH patients receive regular screening for early detection of any hearing problems.

Having an autoimmune disease like Hashimotos increases your risk of developing other autoimmune diseases, including several that can cause hearing loss.

Patients with autoimmune Hashimotos face a higher risk of developing autoimmune inner ear disease, or AIED. In AIED, as antibodies target the inner ear, inflammation can lead to tinnitus and later progress to fluctuating, progressive, or sudden sensorineural hearing loss in both ears. Heres a reason to seek evaluation immediately: When recognized and treated early, AIED can be reversible.

Hashimotos and hypothyroidism patients are also at higher risk of developing Menieres disease, an autoimmune disease that affects the inner ear. Menieres disease symptoms include tinnitus, vertigo, a feeling of fullness in the ear, and sensorineural hearing loss. A recent study concluded that the rates of hypothyroidism in Meniere's patients are so high that all Meniere's patients should receive thyroid screening. That same study reported that after 12 weeks of optimal hypothyroidism treatment, all the Menieres patients studied experienced improvement in their hearing.

Many different drugs can cause hearing loss. You should also be aware of other hearing-related complications of thyroid conditions, including:

According to audiologist Dr. Timothy Teague of Hearing Consultants, it's "possible to diagnose and treat thyroid issues before they impact your hearing." Familiarize yourself with the signs and symptoms of hypothyroidism, and if you have any concerns, see your health professional for thyroid blood tests. Endocrinologist Dr. Sapna Shah recommends that patients who want to get started right away order their own thyroid tests. According to Dr. Shah, "Testing for hypothyroidism is easy and affordable with an at-home thyroid test kit."

Many hearing experts recommend that patients get a hearing test and audiogram after a new diagnosis of hypothyroidism. The results can serve as a baseline to monitor hearing changes in the future.

For people already diagnosed and treated with hypothyroidism, here are three key steps to keep in mind:

Martha began noticing hearing issues around the time of her thyroid diagnosis more than a decade ago. "It wasnt profound, and I figured I could adapt." The pandemic changed things for Martha, however. Says Martha: "Wearing face masks really highlighted how much I had come to rely on lip-reading and visual facial cues when communicating! I decided to get tested when my sorority sisteran audiologisttold me not to wait until my hearing degraded too much."

As for me, the next time I notice hearing problems, I won't wait a week. Instead, I'll take Dr. Shahs advice: "If you notice that your hearing is worsening, I recommend meeting with your health care provider right away. Early diagnosis and treatment are essential."

To find a hearing healthcare professional at a clinic in your area, visit our directory of consumer-reviewed clinics. The sooner you reach out for help, the better your outcome will be.

See the original post:
Hypothyroidism can cause hearing loss and tinnitus - Healthy Hearing

Posted in Hormone Replacement Therapy | Comments Off on Hypothyroidism can cause hearing loss and tinnitus – Healthy Hearing

What is a Cancer treatment & what are the types of cancer treatments? – News Track English

Posted: March 25, 2022 at 2:34 am

In this article, Dr. Sandeep Nayak, who gives one of the Best Cancer Treatments in Banglore talks about "What is a Cancer treatment & what are the types of cancer treatments?

Dr. Nayak is a well-known Surgical Oncologist (cancer surgeon) in Bangalore and is widely regarded as one of the city's best. He is widely acknowledged as a pioneer in the field of robotic and laparoscopic cancer surgery (surgery). He is also a professor and head of the Rajiv Gandhi University of Health Science's Department of Minimal Access Surgical Oncology.Cancer therapy includes the application of surgical procedures, radiation, medications, and other modalities to cure or shrink cancer, as well as the prevention of cancer from spreading.

There are numerous cancer treatments available. Depending on the circumstances surrounding your case, you may receive a single treatment or a combination of treatments to resolve your health problem.

Cancer therapies include the following:

Treatment as the first line of defense

The basic goal of cancer treatment is to completely remove cancer from the body or to destroy all cancer cells discovered.

Although any cancer treatment can be used as the main cancer treatment, surgery is the most frequently utilized primary cancer treatment for the most prevalent types of cancer. Additionally, surgery is the most frequently used secondary cancer treatment.

Your primary treatment may be radiation therapy or chemotherapy if your cancer is highly responsive to either of these medications says Dr. Sandeep Nayak a Top Oncologist in Bangalore.

Dr. Sandeep Nayak is also mentioned in some of the top sites like Practo, Clinicspots, Lybrate as one of the top Oncologists in India.

Palliative care is a type of treatment that relieves suffering

Palliative care may be used to decrease both the side effects of cancer treatment and the signs and symptoms of cancer. Surgery, radiation, chemotherapy, and hormone therapy are all possible treatments for the illness and its symptoms.. Pain and shortness of breath are two symptoms that may be relieved by other drugs.

Palliative treatment can be used in conjunction with other cancer treatments that are meant to cure cancer.

Different Types of Cancer Treatment

Bangalore-based Dr. Sandeep Nayak a leading Oncologist notes that There are many different types of cancer treatment available. The forms of cancer therapy you receive will be determined by the type of cancer you have and how far along it has progressed.

Some cancer patients will only require a single course of treatment. However, the vast majority of patients receive a combination of therapies, including surgery along with chemotherapy and radiation therapy.

When you are diagnosed with cancer and need treatment, there is a lot to understand and consider. It is typical to feel overwhelmed and befuddled during this time. However, discussing with your doctor and learning about the different sorts of treatment you may be eligible for might help you feel more in command of your situation.

Testing for Cancer Biomarkers in the Treatment of the Disease

It is possible to test for genes, proteins, and other substances (known as biomarkers or tumor markers) that can reveal information about cancer through the use of biomarker testing. Biomarker testing can assist you and your doctor in making a treatment decision for cancer.

Chemotherapy

Chemical therapy (sometimes known as chemotherapy) is a type of cancer treatment in which medicines are used to kill cancer cells.

Hormone Replacement Therapy

Treatment with hormones can reduce or even stop the growth of breast and prostate cancers, which are known to use hormones to fuel their growth.

Hyperthermia

High-temperature treatment (hyperthermia) is a method of cancer treatment in which bodily tissue is heated to temperatures as high as 113 degrees Fahrenheit in order to destroy and kill cancer cells that cause little or no injury to normal tissue.

Photodynamic Therapy

Photodynamic therapy is a type of cancer treatment that uses a medication that is triggered by light to kill cancer and other aberrant cells.

Rife Therapy is a type of radiation treatment

In this treatment of cancer, radiation therapy is a sort of treatment that use high doses of radiation to kill cancer cells while also shrinking tumors

Transplantation of Stem Cells

Stem cell transplants are treatments that are used to replace stem cells that have been killed by heavy doses of chemotherapy or radiation therapy in persons who have lost their ability to produce blood cells

Surgery

Surgery is a method in which a surgeon removes cancer from your body when it is being used to treat cancer in patients

Therapeutic Intervention with a Specific Goal

It is also known as targeted therapy, it is a sort of cancer treatment that specifically targets the alterations in cancer cells that aid in their growth, division, and dissemination opines Dr. Sandeep Nayak one of the top Oncologists in Banglore.

Dr. Gurneet Singh Sawhney Talks About DBS Surgery in Mumbai!

Due to a rare disease, the leg had become 50 kg, the operation went on for 90 hours

Moderna seeks to apply FDA for clearance to vaccinate children under the age of 6

View post:
What is a Cancer treatment & what are the types of cancer treatments? - News Track English

Posted in Hormone Replacement Therapy | Comments Off on What is a Cancer treatment & what are the types of cancer treatments? – News Track English

Page 504«..1020..503504505506..510520..»